77 results about "Subtilisins" patented technology

The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

The invention relates to a preparation method and application of an electrochemical immunosensor for a biomarker, namely a recombinant proprotein convertase subtilisin kexin type 9 (pcsk9) protein for predicting and diagnosing cardiovascular diseases, and belongs to the technical field of electrochemical detection. The preparation method is characterized by comprising the following steps: firstly, performing nitrogen doping on a graphene nanobelt (n-gnrs), performing amination on a fullerene-palladium-platinum nanoparticle (n-C60/pdpt) composite material and a staphylococcus aureus a protein (spa), and performing layer-by-layer self-assembling so as to immobilize a pcsk9 antibody (ab1); mixing the synthesized nanoparticle-poly-methylene blue (pt-pmb) with the pcsk9 antibody (ab2), and preparing a nano beacon, thereby obtaining the electrochemical immunosensor for pcsk9 protein detection. The electrochemical immunosensor has the advantages of being high in sensitivity, good in specificity and rapid and convenient in detection. A novel method for pcsk9 protein detection is provided, and useful information is provided for clinical prediction and diagnosis on cardiovascular diseases.

The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.

The present invention relates to mutants of a parent Trichoderma strain, comprising a polynucleotide encoding a polypeptide and one or more (several) genes selected from the group consisting of a first subtilisin-like serine protease gene, a first aspartic protease gene, a trypsin-like serine protease gene, a second subtilisin-like serine protease gene, and a second aspartic pro-tease gene, wherein the one or more (several) genes are modified rendering the mutant strain deficient in the production of one or more (several) enzymes selected from the group consisting of a first subtilisin-like serine protease, a first aspartic protease, a trypsin-like serine protease, a second subtilisin-like serine protease, and a second aspartic protease, respectively, compared to the parent Trichoderma strain when cultivated under identical conditions. The present invention also relates to methods of producing a polypeptide in such mutants and methods for producing such mutants.

The invention relates to a seafood seasoning and a preparation method thereof. Fishes, shrimps, shellfishes or leftovers thereof are taken as raw materials, ingredients are added, and the seafood seasoning is a granular product prepared by the steps of double-enzyme hydrolysis, vacuum concentration, spray drying and granulation. Compared with the prior art, the preparation method of the seafood seasoning has the advantages that: double enzymes, namely subtilisin and flavourzyme are used for performing protein hydrolysis on low-value fishes, shrimps, shellfishes or leftovers thereof, and the proportion, adding amount, hydrolysis temperature, pH value and hydrolysis time of the bienzyme are strictly controlled, so the higher hydrolysis degree can be obtained, and the bitterness is furthest avoided; and the granular seafood seasoning has a reasonable proportion as well as excellent color, aroma and taste, develops a novel way for high-value utilization of low-value aquatic proteins, and has higher utilization value and broad market prospect.

The present invention provides methods for protein engineering. Specifically, the invention provides methods utilizing site evaluation libraries to design libraries that optimize two or more properties of a protein. The present invention also provides variant subtilisins suitable for various uses.

The present invention relates to variants of serine proteases having decreased immunogenicity relative to their corresponding wild-type proteases. More particularly, the present invention relates to variants having a modified amino acid sequence of a wild-type amino acid sequence, wherein the modified amino acid sequence comprises a deletion and, optionally, a substitution of one or more specifically identified positions corresponding to subtilisin BPN'. The invention further relates to mutant genes encoding such variants and cleaning and personal care compositions comprising such variants.

The invention discloses a recombinant bacterium which is a recombinant methanol nutritional type microzyme containing a glutamine transaminage prosoma gene and a subtilisin type hydrolase gene SAM-P45. The invention also protects the recombinant bacterium as Pichia pastoris GSMTGB, the recombinant bacterium is preserved in CGMCC (address: Datun Road, Chaoyang district, Beijing city, China) on August 25th, 2009, the preserving number is CGMCC No.3249, and the enzyme activity of the glutamine transaminage reaches 0.43u/ml when the recombinant bacterium is induced and fermented for 72 hours.

The invention relates to a cervical cell Warburg effect simple detection reagent as well as a preparation method and application thereof. The reagent is composed of a reagent A, a reagent B, a reagent C and a reagent D, wherein the reagent A is 4-6% of a subtilisin isotonic solution; the reagent B is an acetate buffer solution of which the pH value is 3.5-6.0; the reagent C is composed of a 3,3'5,5' tetramethyl benzidine solution with the concentration of 0.1-0.25g/L, a 6-methoxy quinoline solution with the concentration of 1.0-2.5mL/L and a cumene hydroperoxide solution with the concentration of 2-5mL/L; and the reagent D is composed of 0.03-0.07% of a toluidine blue O solution and a triton x-100 solution with the concentration of 2.5-7.5mL/L. The reagent can be used for qualitatively detecting the contents of cellular free ferroprotoporphyrin and active oxygen of cervical exfoliated cells so as to judge the strength of the Warburg effect of cervical cells.